You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »
 

Anti-GTPase HRAS antibody [H-Ras-03] - Activation site (ab64705)

CodeSizePriceAbpointsAvailability
    
 
  • -
  •   
  •   
  •   
  •  
  •   
  •   
Updating...

Overview

Product name

Anti-GTPase HRAS antibody [H-Ras-03] - Activation site
See all GTPase HRAS products (5) ...

Description

Mouse monoclonal [H-Ras-03] to GTPase HRAS - Activation site

Tested applications

WB, ELISAmore details

Cross reactivity

Reacts with

Human

Predicted to work with

Mouse, Rat, Horse, Chimpanzee, Zebrafish, Opossum

Immunogen

Synthetic peptide: DIHQYREQIKRVKDSDDC, corresponding to internal sequence amino acids 92-109 of Human GTPase HRAS

DIHQYREQIK RVKDSDDC

Positive control

RAJI human Burkitt lymphoma cell line HeLa human cervix carcinoma cell line K562 human Caucasian chronic myeloid leukemia cell line

Properties

Form

Liquid

Storage instructions

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 15mM Sodium Azide
Constituents: PBS, pH 7.4

Concentration

Concentration information loading...

Purity

Protein A purified

Purification notes

ab64705 was purified from ascites by protein-A affinity chromatography. Purity is >95% by SDS-PAGE.

Clonality

Monoclonal

Clone number

H-Ras-03

Isotype

IgG1

  • Western blot - GTPase HRAS antibody [H-Ras-03] - Activation site (ab64705)Western blot - GTPase HRAS antibody [H-Ras-03] - Activation site (ab64705) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab64705 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • ShowHide1 Image

    WB

     WB: Use a concentration ...Read more →

    WB: Use a concentration of 0.5 - 1 µg/ml.Detects a band of approximately 24 kDa (predicted molecular weight: 21 kDa).

  • ShowHide

    ELISA

     ELISA: Use at an assay d...Read more →

    ELISA: Use at an assay dependent dilution.

Target

Function

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity.

Involvement in disease

Defects in HRAS are the cause of Costello syndrome (COSTS) [MIM:218040]; also known as faciocutaneoskeletal syndrome. Costello syndrome is a rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).

Sequence similarities

Belongs to the small GTPase superfamily. Ras family.

Post-translational
modifications

Palmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.

Cellular localization

Cell membrane. Golgi apparatus membrane. Shuttles between the plasma membrane and the Golgi apparatus.

Target information above from: UniProt accessionP01112 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • N-terminally processed antibody
  • c bas/has antibody
  • c H ras antibody
  • C HA RAS1 antibody
  • c has/bas p21 protein antibody
  • c ras Ki 2 activated oncogene antibody
  • c ras Ki 2 protein antibody
  • c-H-ras antibody
  • CTLO antibody
  • G1III6 N ras antibody
  • GTP and GDP binding peptide B antibody
  • GTPase HRas antibody
  • H Ras 1 antibody
  • H ras oncogene antibody
  • H RasIDX antibody
  • H-Ras-1 antibody
  • Ha Ras antibody
  • Ha Ras1 proto oncoprotein antibody
  • Ha-Ras antibody
  • HAMSV antibody
  • HRAS 1 antibody
  • HRAS antibody
  • HRAS1 antibody
  • K ras antibody
  • N ras antibody
  • p19 H RasIDX protein antibody
  • p21 protein antibody
  • p21ras antibody
  • Ras family small GTP binding protein H Ras antibody
  • RASH 1 antibody
  • RASH_HUMAN antibody
  • RASH1 antibody
  • Transformation gene oncogene HAMSV antibody
  • Transforming protein p21 antibody
  • v Ha RAS antibody
  • v Ha ras Harvey rat sarcoma viral oncogene homolog antibody
  • VH Ras antibody
  • vHa RAS antibody
see all

Anti-GTPase HRAS antibody [H-Ras-03] - Activation site images:

  Western blot - GTPase HRAS antibody [H-Ras-03] - Activation site (ab64705)

Western blot - GTPase HRAS antibody [H-Ras-03] - Activation site (ab64705)

All lanes : Anti-GTPase HRAS antibody [H-Ras-03] - Activation site (ab64705) at 0.5 µg/ml

Lane 1 : HeLa human cervix carcinoma cell line
Lane 2 : K567 human leukemia cell line
Lane 3 : RAJI human Burkitt lymphoma cell line


Performed under reducing conditions.

Predicted band size : 21 kDa
Observed band size : 24 kDa (why is the actual band size different from the predicted?)

References for Anti-GTPase HRAS antibody [H-Ras-03] - Activation site (ab64705)

ab64705 has not yet been referenced specifically in any publications.

Publishing research using ab64705? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"